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CD133-positive stem-cell therapy in liver cirrhosis (REALISTIC): 
an open-label, randomised, controlled phase 2 trial
Philip Noel Newsome, Richard Fox, Andrew L King, Darren Barton, Nwe-Ni Than, Joanna Moore, Christopher Corbett, Sarah Townsend, 
James Thomas, Kathy Guo, Diana Hull, Heather A Beard, Jacqui Thompson, Anne Atkinson, Carol Bienek, Neil McGowan, Neil Guha, 
John Campbell, Dan Hollyman, Deborah Stocken, Christina Yap, Stuart John Forbes
Summary
Background Results of small-scale studies have suggested that stem-cell therapy is safe and effective in patients with 
liver cirrhosis, but no adequately powered randomised controlled trials have been done. We assessed the safety and 
efficacy of granulocyte colony-stimulating factor (G-CSF) and haemopoietic stem-cell infusions in patients with 
liver cirrhosis.
Methods This multicentre, open-label, randomised, controlled phase 2 trial was done in three UK hospitals and 
recruited patients with compensated liver cirrhosis and MELD scores of 11·0–15·5. Patients were randomly assigned 
(1:1:1) to receive standard care (control), treatment with subcutaneous G-CSF (lenograstim) 15 µg/kg for 5 days, or 
treatment with G-CSF for 5 days followed by leukapheresis and intravenous infusion of three doses of CD133-positive 
haemopoietic stem cells (0·2 × 10⁶ cells per kg per infusion). Randomisation was done by Cancer Research UK Clinical 
Trials Unit staff with a minimisation algorithm that stratified by trial site and cause of liver disease. The coprimary 
outcomes were improvement in severity of liver disease (change in MELD) at 3 months and the trend of change in 
MELD score over time. Analyses were done in the modified intention-to-treat population, which included all patients 
who received at least one day of treatment. Safety was assessed on the basis of the treatment received. This trial was 
registered at Current Controlled Trials on Nov 18, 2009; ISRCTN, number 91288089; and the European Clinical Trials 
Database, number 2009-010335-41.
Findings Between May 18, 2010, and Feb 26, 2015, 27 patients were randomly assigned to the standard care, 26 to the 
G-CSF group, and 28 to the G-CSF plus stem-cell infusion group. Median change in MELD from day 0 to 90 was 
–0·5 (IQR –1·5 to 1·1) in the standard care group, –0·5 (–1·7 to 0·5) in the G-CSF group, and –0·5 (–1·3 to 1·0) in 
the G-CSF plus stem-cell infusion group. We found no evidence of differences between the treatment groups and 
control group in the trends of MELD change over time (p=0·55 for the G-CSF group vs standard care and p=0·75 for 
the G-CSF plus stem-cell infusion group vs standard care). Serious adverse events were more frequent the in G-CSF 
and stem-cell infusion group (12 [43%] patients) than in the G-CSF (three [11%] patients) and standard care (three [12%] 
patients) groups. The most common serious adverse events were ascites (two patients in the G-CSF group and 
two patients in the G-CSF plus stem-cell infusion group, one of whom was admitted to hospital with ascites twice), 
sepsis (four patients in the G-CSF plus stem-cell infusion group), and encephalopathy (three patients in the G-CSF 
plus stem-cell infusion group, one of whom was admitted to hospital with encephalopathy twice). Three patients died, 
including one in the standard care group (variceal bleed) and two in the G-CSF and stem-cell infusion group 
(one myocardial infarction and one progressive liver disease).
Interpretation G-CSF with or without haemopoietic stem-cell infusion did not improve liver dysfunction or fibrosis 
and might be associated with increased frequency of adverse events compared with standard care.
Funding National Institute of Health Research, The Sir Jules Thorn Charitable Trust.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Chronic liver disease is a common cause of death 
globally, the incidence of which is rising due to a 
combination of alcohol consumption, obesity, and viral 
hepatitis.1,2 Although the primary causes of injury, such 
as alcohol or viruses can be removed or treated, patients 
with cirrhosis often still have progression to liver 
decompensation leading to death.3 For such patients, the 
only proven treatment is liver transplantation, but access 
to this approach is limited globally by the shortage of 
donors, sequelae of long-term immunosuppression, and 
high lifelong medical costs.
Promising preclinical data have suggested that 
injections of bone-marrow-derived cells can reduce 
hepatic fibrosis and stimulate liver regeneration, 
thereby improving the synthetic function of the liver,4–6 
Lancet Gastroenterol Hepatol 
2018; 3: 25–36
Published Online 
November 7, 2017 
http://dx.doi.org/10.1016/ 
S2468-1253(17)30326-6
See Comment page 3
National Institute for Health 
Research Liver Biomedical 
Research Unit, University 
Hospitals Birmingham NHS 
Foundation Trust and the 
University of Birmingham, 
Birmingham, UK 
(Prof P N Newsome PhD, 
R Fox MSc, A L King PhD, 
D Barton BSc, 
N-N Than MRCP[UK], 
C Corbett MD, 
S Townsend MBChB, K Guo MSc, 
D Hull MSc, H A Beard PhD); 
Centre for Liver Research, 
Institute of Immunology and 
Immunotherapy, University of 
Birmingham, Birmingham, UK 
(Prof P N Newsome, A L King, 
N-N Than, K Guo, D Hull); Liver 
Unit, University Hospitals 
Birmingham NHS Foundation 
Trust, Birmingham, UK 
(Prof P N Newsome, A L King, 
N-N Than, S Townsend); 
University of Birmingham, 
NIHR Liver BRU Clinical trials 
group, Cancer Research UK 
Clinical Trials Unit, 
Birmingham, UK (D Barton, 
C Yap PhD, R Fox); Medical 
Research Council Centre for 
Regenerative Medicine, 
University of Edinburgh, 
Edinburgh, UK (J Moore MBChB, 
J Thomas PhD, 
Prof S J Forbes FRCP Ed); 
National Institute for Health 
Research Biomedical Research 
Unit in Gastrointestinal and 
Liver Diseases, Nottingham 
University Hospitals NHS Trust 
and the University of 
Nottingham, Nottingham, UK 
(N Guha FRCP); Cellular and 
Molecular Therapies, NHSBlood 
and Transplant, Birmingham, 
UK (H A Beard, J Thompson BSc, 
D Hollyman PhD); Scottish 
Articles
26 www.thelancet.com/gastrohep   Vol 3   January 2018
National Blood Transfusion 
Service, Edinburgh, UK 
(A Atkinson BSc, C Bienek PhD, 
N McGowan PhD, 
Prof J Campbell PhD); and 
Newcastle University, 
Newcastle Clinical Trial Unit, 
Institute of Health and Society, 
Newcastle, UK (D Stocken PhD)
Correspondence to: 
Prof Philip N Newsome, National 
Institute for Health Research 
Liver Biomedical Research Unit, 
University Hospitals Birmingham 
NHS Foundation Trust and the 
University of Birmingham, 
Birmingham B15 2TT, UK 
P.N.Newsome@bham.ac.uk
although the mechanisms by which these effects are 
achieved have not been clearly elucidated.7 There have 
also been a series of proof-of-concept clinical studies, 
as reviewed by Moore and colleagues,8 in which 
infusions of bone-marrow-derived stem cells have 
potentially accelerated hepatic regeneration and 
improved liver dysfunction in the setting of liver 
fibrosis or cirrhosis.9,10 However, these effects are not 
universally detected between studies and when seen 
are not always durable.10 Nevertheless, infusions of 
stem cells in patients with liver disease have been 
reported to be safe, except in studies in which cells 
were administered via the portal vein.11
The size and nature of the trial designs of many of the 
previous studies make it impossible to draw meaningful 
conclusions on clinical outcomes, and thus the efficacy 
of bone-marrow-derived stem cells for liver cirrhosis has 
yet to be proven.8 In one adequately powered randomised 
controlled study, whole bone marrow mononuclear cells 
were infused into patients with acute inflammatory 
disease (alcoholic hepatitis), but had no effect.12 However, 
alcoholic hepatitis is a rarer and entirely different 
clinicopathological entity to that seen in patients with 
compensated liver cirrhosis, in which there is minimal 
inflammation and fibrosis is the major feature. 
Furthermore the mononuclear cells infused contained a 
mixed cell population.
Because liver cirrhosis is a chronic condition and a single 
dose of cells might have little effect, as suggested in a 
previous study0 we reasoned that multiple administrations 
of stem cells might have a greater antifibrotic effect, which 
was supported by our preclinical findings.6 We therefore 
designed a sufficiently powered, randomised controlled 
trial of granulocyte colony-stimulating factor (G-CSF) with 
or without repeated haemopoietic stem-cell (HSC) therapy 
in patients with compensated liver cirrhosis to detect 
clinically important effects on liver function and liver 
fibrosis and to assess safety.
Research in context
Evidence before this study
We (JM/SJF) searched MEDLINE and Embase in July, 2013, to 
find clinical studies involving patients with liver disease 
(any language) who had received autologous cellular therapy. 
To find relevant clinical studies we used the search terms 
“liver”, “cell”, “therapy”, “treatment”, “failure”, 
“decompensated”, “autologous”, “cell transplantation”, and 
“cell therapy”. Abstracts were assessed by two independent 
reviewers and the full text versions of studies that were 
relevant were analysed. Bibliographies of these papers and 
reviews were also studied, along with clinical trial websites 
(www.clinicaltrialresults.org and www.controlled-trials.com/
ukctr) and abstract books from international liver conferences 
for the past 3 years. Studies chosen had to contain patients 
with chronic liver disease, who had received autologous stem 
cells (any route) along with outcome data covering safety and 
feasibility as a principal outcome. A range of secondary 
outcomes (prognostic liver scores, survival and changes in 
liver blood tests) were also looked at if relevant. Given the 
lack of randomised controlled studies, all trial designs 
were considered.
Most of the identified studies were small cohort, safety, and 
feasibility studies (median of ten treated patients) with fairly 
short follow-up (median 6 months). We found only 
six randomised controlled trials, but comment was not always 
made on how the patients were randomised; therefore, only 
one study was of good quality. There was heterogeneity across 
studies in outcome measures, causes of liver disease, dose, type, 
and route of cells given. Significant improvement in liver 
function tests was seen after treatment in 16 studies, 
suggesting that stem-cell administration might be associated 
with accelerated hepatic regeneration and improved liver 
dysfunction in liver fibrosis and cirrhosis. These effects were not 
universally observed across studies and when seen were not 
always durable. With the exception of studies in which cells 
were administered via the portal vein, infusions of stem cells in 
patients with liver disease were safe.
Added value of this study
To our knowledge, REALISTIC is the first multicentre, 
open-label, randomised, controlled phase 2 trial of either 
granulocyte colony-stimulating factor (G-CSF) alone or in 
conjunction with repeated infusions of purified autologous 
haemopoietic stem cells for patients with compensated 
chronic liver disease. The study was sufficiently powered to 
detect clinically important effects in liver function with the 
MELD score, which is the clinically recognised parameter for 
this purpose, and is predictive of future mortality. Our results 
showed that, in the setting of liver cirrhosis, no improvement 
in liver dysfunction or markers of liver fibrosis occurred after 
the administration of G-CSF or G-CSF plus stem-cell infusions. 
This study is of value to the field as it challenges the findings 
of other reports that show bone marrow cell therapy plus 
G-CSF to be effective for improving liver function in 
decompensated cirrhosis and acute-on-chronic liver failure. 
Our results also suggest that such therapies might even 
increase patient morbidity.
Implications of all the available evidence
The burgeoning clinical burden of chronic liver disease and 
absence of effective therapies has led to the consideration of 
innovative approaches, such as stem-cell therapies. Although 
this should be encouraged, it is important to ensure that 
decisions on the effectiveness of such new therapies are judged 
in the setting of robust randomised controlled trials that adhere 
to recognised regulatory standards. Our findings show that 
G-CSF with or without haemopoietic stem-cell infusions does 
not improve liver function or reduce liver fibrosis. Moreover, 
this approach might increase patients’ risk of adverse events.
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Methods
Study design and participants
The REpeated AutoLogous Infusions of STem cells 
In Cirrhosis (REALISTIC) trial was a multicentre, 
open-label, randomised, controlled phase 2 trial done at 
three hospitals in Birmingham, Edinburgh, and 
Nottingham, UK. The National Research Ethics Service 
(NRES) Oxfordshire REC A committee (REC reference 
09/H0604/64) and the Medicines and Healthcare 
Products Regulatory Agency (MHRA) approved all 
versions of the study protocol. Additionally, all 
recruitment sites obtained approval from their local 
hospital research and development departments. The 
University of Birmingham (Birmingham, UK) acted 
as the sponsor of the trial. A detailed version of the 
REALISTIC protocol has been published.13
The trial entry criteria were based on the presence of 
liver cirrhosis identified on biopsy or on clinical grounds 
as detailed in the appendix (p 3). Participants had to be 
aged 18–75 years with predominantly compensated 
cirrhosis (most causes were allowed except for 
autoimmune hepatitis) and a MELD score of 11·0–15·5.
Exclusion criteria were average alcohol ingestion 
greater than 21 units per week for men or greater than 
14 units for women, any alcohol consumption within 
6 months for patients with alcohol-related liver disease, 
ascites unless deemed by the investigator to be minimal 
and well controlled with no changes to diuretic therapy in 
the past 3 months, encephalopathy that was either current 
or required hospital admission for treatment in the past 
3 months, portal hypertensive bleeding with an episode 
requiring treatment or hospital admission in the past 
3 months, previous or current history of hepatocellular 
carcinoma, presence of dysplastic or indeterminate 
nodules, previous liver transplant (or being on a list for a 
transplant), and recent history of pulmonary infiltrates or 
pneumonia. All patients with hepatitis C virus (HCV) 
infection had to have received previous antiviral treatment 
before being considered for the trial, but none had 
cleared the virus after treatment and thus all had ongoing 
viral injury.
We recruited participants from among patients attending 
the liver clinics. All patients gave written informed consent, 
the study was done by site investi gators, and data were 
gathered by specifically trained personnel.
Randomisation
Centre-delegated staff telephoned randomisation officers 
at the Cancer Research UK Clinical Trials Unit (CRCTU; 
Birmingham, UK), who used a computer-generated, 
centrally administered procedure to randomly assign 
eligible patients (1:1:1) to one of three treatments: 
standard care alone, G-CSF, or G-CSF plus stem-cell 
infusion. Randomisation was based on a minimisation 
algorithm (prepared and validated by the CRCTU 
programming and statistical team) and patients were also 
stratified by trial site and cause of disease (alcohol-related 
liver disease, HCV, and other). Each patient was then 
allocated a unique patient trial number and scheduled 
for treatment and follow-up visits. The local site staff 
could not predetermine treatment allocation, the 
treatment allocation was open, and all clinicians and 
local site staff, as well as the patients, were aware of 
which treatment had been allocated (open-label therapy) 
following randomisation.
Procedures
All patients received standard management for 
compensated cirrhosis, which could include disease-
specific medications and treatments for the compli-
cations of cirrhosis. Patients assigned to the control 
group received standard of care management alone. 
Patients assigned to the G-CSF group received 
subcutaneous injections of G-CSF (lenograstim; 
Chugai Pharmaceuticals, London, UK) at 15 µg/kg 
bodyweight daily for 5 consecutive days. Patients 
assigned to receive G-CSF plus stem cells received 
subcutaneous injections of G-CSF 15 µg/kg bodyweight 
per day for 5 consecutive days and underwent 
leukapheresis and intravenous infusion of three doses 
of CD133-positive haemopoietic stem cells (HSCs; 
0·2 × 10⁶ cells per kg) on days 5, 30, and 60 after 
randomisation. Isolation of CD133-positive HSCs from 
the harvested peripheral blood mononuclear cells was 
done under aseptic conditions within clean room 
facilities in accordance with Good Manufacturing 
Practice regulations (MHRA/HTA, UK). Cell sorting 
was done in a closed, sterile system to provide clinical 
grade enrichment (CliniMACS Plus, Miltenyi Biotec, 
Bergisch Gladbach, Germany).
Cells were tested with flow cytometry (CD45-positive, 
CD34-positive, and CD133-positive) on the day of isolation 
to establish positive and negative fractions. The gating 
strategy was set up to exclude debris, beads, and non-viable 
cells, before gating on CD45 and then CD133 expression 
such that total cells included were viable and positive for 
CD45 and CD133. This information was used to aliquot 
three doses 0·2 × 10⁶ cells per kg for each patient. Cells 
had to have greater than 50% viability, which is in line 
with clinical practice. Fresh CD133-positive HSCs were 
administered intra venously for immediate reinfusion and 
a further two aliquots were cryopreserved according to site 
standard protocols for later reinfusion at day 30 and day 60 
post randomisation, thus requiring the administration of 
a minimum total number of cells of 0·6 × 10⁶ cells per kg. 
Cells for days 30 and 60 were supplied to the ward frozen 
and thawed before being administered; results for sterility 
testing from BacTalert bottles were provided at the same 
time, in line with standard clinical practice for the 
administration of HSCs to patients receiving stem cell 
transplants. If there were insufficient cells for three doses, 
cells were allocated preferentially to the first, then second, 
and then third dose. The procurement, processing, 
storage and distribution of the autologous CD133-positive 
See Online for appendix
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HSCs was done in accordance with Tissue Quality and 
Safety Regulations by establishments holding Human 
Tissue Authority licences.
After randomisation, all patients returned for study 
visits at days 30, 60, 90, 180, and 360 (end of study). The 
coprimary outcomes used data captured from baseline 
to day 90. The schedule for the study visits and data 
collection is summarised in the appendix (p 5).
Outcomes
The coprimary outcome measures were change in MELD 
score at 90 days from baseline and the trend of treatment 
activity established by incorporating MELD score 
measured at baseline and days 30, 60, and 90. The 
protocol was updated in March, 2015, to include the 
second coprimary outcome to make better use of data 
collected and detect differences before 90 days. MELD 
score is calculated from objective variables that are 
readily obtained: serum bilirubin, serum creatinine, 
and International Normalised Ratio (INR).14 Secondary 
outcome measures were liver stiffness (Fibroscan), 
enhanced liver fibrosis (ELF) test, Chronic Liver Disease 
Questionnaire (CLDQ) scores, individual components of 
liver function (bilirubin, albumin, INR, and creatinine 
values [creatinine was unplanned]), UK End-Stage Liver 
Disease (UKELD) score, circulating peripheral blood 
HSCs, long-term MELD and UKELD (to day 360), clinical 
events, and transplant-free survival.
Safety and adverse events were assessed with standard 
reporting forms by trained investigators. The reporting 
period for adverse events started from the date of patient 
consent and continued throughout the study until 
visit 7 (day 360). Serious adverse events were reported 
from date of consent until 30 days after the last possible 
stem-cell infusion (day 90) for all treatment groups, 
therefore ensuring that the reporting period stayed the 
same for all treatment groups. All serious adverse events 
and adverse events were assessed by the local investigators 
and recorded. We used the National Cancer Institute’s 
common terminology criteria for adverse events (CTCAE 
version 4.02–2010) to grade each adverse event. The 
CRCTU kept detailed records of all adverse events 
reported (nature, onset, duration, severity, and outcome) 
and did an assessment with respect to seriousness, 
causality, and expectedness.
Statistical analysis
The sample size calculation was based on the 
change in MELD score from baseline to 90 days 
after randomisation. With pooled standard deviation 
assumed to be 1·25 in this controlled setting, the trial 
aimed to detect a standardised effect size of at least 0·8 
between treatment groups and the control group, which 
would equate to a 1 point reduction in MELD. To have 
error rates based on two-sided α of 0·05 (α=0·10 split 
equally between the two hypotheses) and 80% power, we 
needed to recruit 27 patients into each group.13 The trial 
was designed as a three-armed study with one control 
group and was powered to compare each treatment to 
control with respect to the first coprimary outcome, but 
was not powered to detect differences between the 
two treatment groups.
The hypothesis of the primary analysis was designed 
to assess activity and, as such, all analyses were done in 
the modified intention-to-treat (mITT) population. The 
mITT population included all participants who received 
at least one day of treatment (one day of G-CSF at 
15 µg/kg bodyweight in the treatment groups, plus one 
infusion of at least 0·17 × 10⁶ cells per kg for the G-CSF 
plus stem-cell infusion group), with patients retained in 
their randomly assigned treatment groups, including 
those who violated the protocol or were ineligible. The 
per-protocol population was defined as any patients who 
received 5 days of G-CSF at an average daily dose of at 
least 12 µg/kg and any patients who received 5 days of 
G-CSF plus three infusions at a minimum of 
0·17 × 10⁶ cells per kg each. All patients in the control 
group were included in the mITT and per-protocol 
populations. We defined the safety population on the 
basis of the actual treatment received.
We calculated the first coprimary outcome, change 
in MELD score from baseline to day 90, for each 
participant and we compared treatment groups with the 
control using the non-parametric two-sample Wilcoxon 
test. We fitted exploratory linear regression models, with 
transformed MELD scores where required, to enable 
adjustment of the estimates of the first coprimary 
outcome. For the second coprimary outcome, we 
explored the effect of treatment on the change in MELD 
score through linear mixed-effects models (details of the 
modelling approach used to find the most appropriate 
parsimonious model are shown in the appendix [p 7]), 
which incorporated measurements taken at baseline and 
at days 30, 60, and 90. We assigned random effects at 
the patient level. The first coprimary outcome was 
conditional on the availability of day 90 MELD measures, 
whereas the second coprimary outcome was not. 
Sensitivity analyses included adjustment of model-based 
analyses for known prognosticators, such as alcohol 
intake and cause of liver disease, minimisation factors, 
and differences at baseline.
We analysed UKELD in the same manner as the 
coprimary outcomes, and we assessed CLDQ responses 
through area-under-curve analyses with a set of varied 
assumptions applied to address censoring, and, as a 
sensitivity analysis, removing participants who had 
major adverse events. We also assessed long-term MELD 
and UKELD, measured to day 360, in the same way as 
the coprimary outcomes. We compared average change 
in liver parameters between treatment groups and the 
control group from baseline using a test appropriate to 
the data (t tests or Wilcoxon rank sum). We report other 
outcome measures descriptively. We used Stata version 14 
for all analyses.
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Data were collected and presented to the independent 
data management committee regularly throughout the 
recruitment, treatment, and follow-up periods of the 
study (appendix p 2). The committee advised the trial 
management team throughout the study in relation 
to trial conduct and specifically whether extra data 
monitoring was needed throughout the trial. The data 
monitoring committee operated in accordance with a 
2 withdrew
2 missed day 90 assessment
27 assigned to standard of care
27 included in mITT analysis
27 included in per-protocol analysis
26 assigned to G-CSF alone
26 included in mITT population
26 included in per-protocol analysis
26 included in mITT analysis
21 included in per-protocol analysis
28 assigned to G-CSF plus CD133-positive
cell infusion
26 received at least one dose of G-CSF and
one cell infusion (mITT)
27 received standard care 26 received at least one dose of G-CSF
1 died before receiving treatment*
1 received no cell infusions
5 received sub-optimum dose
1 apheresis not done because of 
 lack of venous access
1 withdrew from trial treatment
1 admitted to hospital and 
 unable to attend visit
1 unwell so deferred infusion to 
 next visit
1 not enough cells available to 
 infuse
21 received protocol treatment per protocol27 received protocol treatment 26 received protocol treatment per protocol
27 assessed at day 90 23 assessed at day 90 26 assessed at day 90 
72 excluded
33 low MELD
19 high MELD
5 alcohol intake
3 ascites
4 cancer history
3 adverse events
1 declined
4 no reason given
153 patients assessed for eligibility
81 randomly assigned to treatment
Figure 1: Trial profile
We defined the mITT population as including any patient assigned to receive G-CSF who received a minimum of 1 day of G-CSF or any patient assigned to receive 
G-CSF plus stem-cell infusion who received at least one infusion of at least 0·17 × 10⁶ cells per kg. We defined the per-protocol population as including patients in the 
G-CSF group who attended all G-CSF visits and received an average daily dose of at least 12 µg/kg and patients in the G-CSF plus stem-cell infusion group who 
received 5 days of G-CSF and a cumulative cell infusion of at least 0·51 × 10⁶ cells per kg. All patients in the standard care group were included in the mITT and 
per-protocol populations. Because the second coprimary outcome allowed imputation of missing values, the mITT numbers are greater than the number of available 
day 90 values. mITT=modified intention to treat. G-CSF=granulocyte colony-stimulating factor. *Patient received no treatment so the event is attributed to the 
standard care group based on definition of the safety population.
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trial-specific charter based on the template created by the 
Damocles Group. This trial was registered at Current 
Controlled Trials on Nov 18, 2009; ISRCTN, number 
91288089; and the European Clinical Trials Database, 
number 2009-010335-41.
Role of the funding source
The funders had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report. 
The corresponding author had access to all data in the 
study and had final responsibility for the decision to 
submit for publication.
Results
Between May 18, 2010, and Feb 6, 2015, 153 patients 
with liver cirrhosis were screened, and 81 underwent 
randomisation (figure 1). We recruited 58 patients from 
the Birmingham centre, 19 from the Edinburgh centre, 
and four from the Nottingham centre. The 81 patients 
recruited were not equally allocated to the treatment 
groups, because the minimisation procedure allocated 
patients to ensure that groups were balanced with respect 
to the specified minimisation factors. The final patient’s 
characteristics resulted in a balanced state and hence the 
allocation was made randomly to the G-CSF plus 
stem-cell infusion group. The mITT population included 
27 patients in group 1, 26 patients in group 2, and 
26 patients in group 3, whereas the per-protocol 
population included 27 patients in group 1, 26 patients in 
group 2, and 21 patients in group 3. In group 3, one 
patient received no G-CSF nor any cells (this patient later 
died after 2·3 months), one patient received G-CSF only 
(withdrew from study), and a further five patientsreceived 
G-CSF but did not receive sufficient cells to complete 
three full doses (appendix p 13).
At baseline, we noted differences between the 
treatment groups in terms of gender, urea, and creatinine 
(table 1). Patients had features of liver decompensation 
(ascites, encephalopathy, and prior variceal bleeding), 
although these were mild and responsive to standard 
medical treatment. The median MELD score was 13·1 
(IQR 12·4–13·8) in the standard treatment group, 12·7 
(12·0–13·1) in the G-CSF group, and 13·2 (12·1–13·9) in 
the G-CSF plus stem-cell infusion group. 22 patients 
had previous histological confirmation of liver cirrhosis.
In the mITT population, day 90 MELD scores were 
obtained from 23 of 27 patients in the standard care 
group, and all patients in each of the treatment groups 
(figure 1). Median change in MELD from day 0 to 90 was 
–0·5 (IQR –1·5 to 1·1) in the standard care group, –0·5 
(–1·7 to 0·5) in the G-CSF group, and –0·5 (–1·3 to 1·0) 
in the G-CSF plus stem-cell infusion group. We found no 
evidence of a difference in change in MELD scores 
between days 0 and 90 in either of the treatment groups 
compared with the standard care group (p=0·72 for 
G-CSF vs standard care and p=0·90 for the G-CSF plus 
stem-cell infusion group vs standard care). Waterfall 
plots of day 90 change in MELD score and best change in 
MELD score are presented in the appendix (pp 15, 16).
Simple mixed-effects models showed no evidence of a 
trend in MELD over time (p=0·33 for all groups), nor of a 
difference between the treatment and control groups 
(p=0·55 for the G-CSF group vs the standard care group 
and p=0·75 for the G-CSF plus stem-cell infusion group 
vs the standard care group). The final, more flexible 
model for the second coprimary outcome included a 
Standard care (n=27) G-CSF only (n=26) G-CSF plus 
CD133-positive cell 
infusion (n=28)
Demographics
Age (years) 52·0 (47·0–60·0) 54·0 (49·0–61·0) 56·5 (47·5–62·5)
Gender
Male 13 (48%) 18 (69%) 22 (79%)
Female 14 (52%) 8 (31%) 6 (21%)
BMI 27·9 (24·5–35·8) 27·4 (25·0–31·3) 30·6 (27·5–34·6)
Cause of liver disease
Alcohol-related liver disease 12 (44%) 12 (46%) 14 (50%)
Hepatitis C 4 (15%) 3 (12%) 3 (11%)
Other causes 11 (41%) 11 (42%) 11 (39%)
Non-alcoholic fatty liver disease 5 (19%) 3 (12%) 5 (18%)
Primary biliary cholangitis 5 (19%) 7 (27%) 3 (11%)
Cryptogenic 0 (0%) 1 (4%) 2 (7%)
Mixed 1 (4%) 0 1 (4%)
Liver disease severity
MELD 13·1 (12·4–13·8) 12·7 (12·0–13·1) 13·2 (12·1–13·9)
UKELD 51·5 (49·8–54·2) 51·1 (50·0–52·5) 52·0 (50·9–53·5)
Child-Pugh score 7·0 (7·0–8·0) 7·0 (6·0–8·0) 7·0 (6·0–8·0)
Child-Pugh (class)
A 6 (22%) 7 (27%) 11 (39%)
B 20 (74%) 19 (73%) 16 (57%)
C 1 (4%) 0 0
Unknown 0 0 1 (4%)
Liver comorbidities
Ascites 13 (48%) 10 (39%) 14 (50%)
Variceal bleeding 7 (26%) 11 (42%) 11 (39%)
Encephalopathy 3 (11%) 3 (12%) 7 (25%)
Medications
ACE inhibitor 1 (4%) 2 (8%) 3 (11%)
Angiotensin receptor 
antagonists
0 0 1 (4%)
Antiviral 0 0 0
Diuretic 8 (30%) 14 (54%) 14 (50%)
Lactulose 7 (26%) 7 (27%) 3 (11%)
Neomycin 0 1 (4%) 0
Rifaximin 2 (7%) 1 (4%) 0
Other 23 (85%) 23 (88%) 22 (79%)
Full blood count
Haemoglobin (g/dL) 12·9 (11·8–13·8) 13·1 (11·6–14·3) 12·9 (12·1–14·3)
White blood cells (× 10⁹ per L) 4·2 (3·3–5·4) 4·3 (3·4–5·2) 4·3 (3·3–5·3)
Platelets (× 10⁹ per L) 77·0 (57·0–92·0) 90·5 (54·0–116·0) 78·5 (57·0–106·5)
(Table 1 continues on next page)
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change-point at day 30 and an interaction between 
treatment group and time to allow for different trends in 
each period (appendix p 7). Despite an improved fit, we 
found no evidence of a difference in trends in either 
model (figure 2). In the per-protocol population the 
median change in MELD score from day 0 to 90 was –0·5 
(–1·5 to 1·1) in the standard care group, –0·5 (–1·7 to 0·5) 
in the G-CSF group, and –0·7 (–1·1 to 0·7) in the G-CSF 
plus stem-cell infusion group, with no evidence of 
differences between treatment and control groups 
(p=0·72 for G-CSF vs standard care and p=0·90 for 
G-CSF plus stem-cell infusion vs standard care). We 
found no evidence of any differences in analyses with the 
second coprimary outcome in the per-protocol popu-
lation. Inferences were unchanged for both coprimary 
outcome measures when adjusted for participant 
characteristics, including cause of liver disease, alcohol 
consumption history, and the baseline imbalances 
between the groups (appendix pp 10–12).
We detected no evidence of any differences in UKELD 
scores between groups (figure 2), and no differences 
in either composite or individual markers of liver 
dysfunction across any of the groups (table 2). Moreover, 
we found no differences in markers of liver fibrosis 
(serum ELF or Fibroscan) or quality of life scores (CLDQ). 
Inferences were unchanged in the per-protocol and 
sensitivity analyses. Change in MELD score was not 
affected by either previous consumption of alcohol 
(appendix p 10) or length of abstinence from alcohol 
(appendix p 11). We also evaluated MELD and UKELD 
scores at days 180 and 360 (appendix p 17), we detected 
no differences between groups. 
Patients in the treatment groups who received G-CSF 
had increases in the number of circulating white blood 
cells, and in CD34-positive and CD133-positive cell 
populations (table 3). Data on the number of HSCs in the 
apheresis and post-isolation cell product are shown in 
the appendix (p 14).
Neither treatment group had a reduction in mortality 
or admissions to hospital compared with the control. 
Patients in both treatment groups had to be considered 
for liver transplantation, and patients in the G-CSF plus 
stem-cell infusion group had more serious adverse 
events (12 [43%] of 28 patients) than patients in the 
G-CSF group (three [11%] of 28 patients) and the standard 
care group (three [12%] of 26 patients; table 4). At the 
time of adjudication, none of the serious adverse events 
were judged to be related to treatment. The frequency of 
adverse events reported by CTCAE category and grade 
was similar between groups, except for nervous system 
disorders and musculoskeletal disorders, which were 
more common in the treatment groups than in the 
standard care group (appendix p 18). Patients were 
monitored for a year, including standard screening 
for hepatocellular carcinoma every 6 months and no 
malignancies were detected. We also followed up 
patients for outcomes such as death, assessment for liver 
transplantation, and serious adverse events up to 1 year 
after randomisation (table 4). Three patients died during 
the study, including one in the standard care group 
(variceal bleed) and two in the G-CSF plus stem-cell 
infusion group (one myocardial infarction and one 
progressive liver disease).
Discussion
In this study, we found that neither G-CSF nor G-CSF 
plus stem-cell infusion showed improvement in MELD 
score in patients with compensated liver cirrhosis. 
These results contrast with the findings of previous 
smaller studies.8
We chose MELD score as the primary endpoint because 
it is an objective prognostic scoring system validated in 
large independent cohorts worldwide for patients with 
Standard care (n=27) G-CSF only (n=26) G-CSF plus 
CD133-positive cell 
infusion (n=28)
(Continued from previous page)
Biochemistry
Sodium (mmol/L) 140·0 (137·0–142·0) 140·0 (137·0–142·0) 139·0 (137·0–140·0)
Potassium (mmol/L) 3·9 (3·7–4·4) 4·0 (3·7–4·2) 4·1 (4·0–4·2)
Urea (mmol/L) 3·7 (2·7–4·2) 3·8 (2·9–4·8) 4·8 (3·7–5·3)
Creatinine (µmol/L) 62·0 (52·0–74·0) 63·0 (56·0–75·0) 71·0 (64·0–90·0)
Liver function tests
Bilirubin (µmol/L) 38·0 (30·0–53·0) 44·0 (34·0–53·0) 41·5 (33·0–51·0)
Albumin (g/L) 33·0 (30·0–37·0) 36·0 (30·0–39·0) 35·5 (33·5–39·0)
Aspartate aminotransferase (U/L) 44·0 (35·0–62·0) 50·5 (37·0–82·0) 48·0 (37·0–62·0)
Alanine aminotransferase (U/L) 28·0 (20·0–39·0) 31·5 (21·0–54·0) 31·0 (21·5–45·0)
Alkaline phosphatase (U/L) 160·0 (108·0–255·0) 142·5 (118·0–282·0) 138·5 (97·5–244·0)
γ glutamyl transpeptidase (g/dL) 68·0 (49·0–110·0) 86·0 (57·0–198·0) 73·0 (41·0–188·5)
α fetoprotein (IU/L) 3·0 (2·0–6·0) 3·0 (2·0–5·0) 3·0 (2·0–5·0)
International Normalised Ratio 1·4 ( 1·2–1·4) 1·2 ( 1·2–1·4) 1·3 ( 1·2–1·4)
Non-invasive hepatic biomarkers
Fibroscan (kPa) 32·5 (22·2–44·8) 34·3 (26·1–66·4) 28·9 (17·3–45·2)
ELF test
ELF score 12·0 (11·2–13·0) 11·9 (11·4–12·6) 12·1 (11·3–13·0)
Hyaluronic acid 490·6 (265·2–879·9) 476·9 (253·8–722·2) 574·4 (366·8–807·5)
Amino-terminal propeptide 
of type III procollagen
17·1 (12·0–22·8) 18·2 (13·0–25·7) 18·7 (13·2–26·4)
Tissue inhibitor of 
metalloproteinases 1
329·3 (267·0–399·1) 372·2 (289·5–507·6) 322·9 (227·1–412·2)
Quality of life score (CLDQ)
Abdominal 6·3 (4·7–7·0) 5·7 (4·0–6·7) 6·0 (4·7–7·0)
Fatigue 4·5 (2·8–6·0) 3·5 (2·6–5·2) 4·2 (3·6–5·2)
Systemic 5·4 (4·0–6·2) 5·4 (4·0–6·0) 5·2 (4·4–6·0)
Activity 6·0 (3·7–7·0) 4·7 (3·2–6·0) 5·8 (4·7–6·8)
Emotion 5·6 (4·5–6·8) 4·8 (3·7–5·8) 5·4 (4·5–6·1)
Worry 5·8 (3·9–6·9) 5·1 (3·3–6·6) 4·8 (3·6–6·4)
Overall 5·5 (3·4–6·3) 4·8 (3·5–5·5) 5·0 (4·2–6·1)
Data are n (%) or median (IQR). G-CSF=granulocyte colony-stimulating factor. ACE=angiotensin-converting enzyme. 
ELF=enhanced liver fibrosis. UKELD=UK End-Stage Liver Disease Score. CLDQ=Chronic Liver Disease Questionnaire.
Table 1: Baseline characteristics
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chronic liver disease. It independently predicts clinical 
decompensation in patients with compensated cirrhosis15 
and is highly accurate in the prediction of 1-week, 
3-month, and 1-year mortality. For any given MELD 
score, the magnitude and direction of change in score 
during the previous 30 days is a significant independent 
predictor of mortality, making change in score a more 
important determinant than initial MELD score alone. 
The magnitude of the change in MELD score can also 
predict the development of complications of cirrhosis 
such as ascites and variceal bleeding. We supplemented 
the use of MELD as a primary endpoint with many 
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Figure 2: Change in MELD and UKELD scores
Observed median change in (A) MELD and (B) UKELD scores at baseline and days 30, 60, and 90. Bars show IQR. Model fit based on predictions from a linear 
mixed-effects model incorporating restricted cubic splines for (C) MELD and (D) UKELD respectively. G-CSF=granulocyte colony-stimulating factor. UKELD=UK 
End-Stage Liver Disease Score.
G-CSF only (n=26) G-CSF plus CD133-positive cell infusion (n=28)
Before G-CSF After G-CSF After to before 
ratio
Before G-CSF After G-CSF After to 
before ratio
White cell count (per µL) 3715·0 
(2920·0–4955·0)
25 605·0 
(21 610·0–33 000·0)
6·8 
(4·5–7·7)
4000·0 
(3180·0–5780·0)
24 600·0 
(18 590·0–35 150·0)
5·7 
(4·4–8·3)
CD34 cell count (per µL) 2·9 
(1·5–4·7)
28·8 
(16·9–50·9)
8·7 
(7·0–16·5)
2·4 
(1·5–3·3)
31·4 
(20·4–36·8)
10·7 
(6·0–22·7)
CD133 cell count (per µL) 2·8 
(1·6–5·0)
24·7 
(14·4–39·3)
8·1 
(5·0–21·4)
2·4 
(1·1–4·1)
21·7 
(16·9–32·2)
13·8 
(4·5–23·0)
CD133-positive CD45low cells per µL 1·2 
(0·5–2·1)
18·7 
(10·9–27·1)
15·4 
(9·9–24·5)
0·8 
(0·5–1·8)
18·8 
(13·2–31·9)
24·6 
(5·6–60·0)
Proportion of CD133-positive cells of 
viable CD45-positive cells
0·1% 
(0·0–0·1)
0·1% 
(0·1–0·1)
1·2% 
(0·9–3·0)
0·1% 
(0·0–0·1)
0·1% 
(0·1–0·1)
1·5% 
(0·7–4·5)
Proportion of CD133-positive CD45low 
cells of viable CD45-positive cells
0·0% 
(0·0–0·1)
0·1% 
(0·0–0·1)
2·1% 
(1·1–4·1)
0·0% 
(0·0–0·1)
0·1% 
(0·1–0·1)
3·1% 
(1·0–6·8)
Data are median (IQR). G-CSF=granulocyte colony-stimulating factor.
Table 2: Circulating leucocyte and haematopoietic stem-cell numbers before and after G-CSF
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secondary endpoints of liver dysfunction, as well as 
markers of liver fibrosis (serum ELF and Fibroscan), 
none of which improved with therapy.
We specifically chose to recruit patients with 
predominantly compensated cirrhosis, as opposed to 
those with more advanced decompensation, in the 
belief that the included patients had a greater potential 
for regeneration and regression of fibrosis. In this 
respect, a tangible effect of stem-cell therapy could have 
been to prevent disease progression that would require 
consideration for liver transplantation. It seems highly 
unlikely that the interventions in this study would be 
more effective in a cohort of patients with more 
advanced decompensated disease given that the fibrosis 
in such patients would be more advanced and less likely 
to be reversible.16
This study has several strengths. It is, to our knowledge, 
the largest and most rigorous randomised controlled trial 
on stem-cell therapy for cirrhosis of the liver thus far, with 
robust clinical trial governance and sufficient power to 
detect a clinically meaningful difference. The trial also 
included a representative spread of causes of liver disease, 
between which we saw no differences in response to the 
interventions (appendix p 12). Moreover, the patients 
Standard care (n=27) G-CSF only (n=26) G-CSF plus CD133-positive cell infusion 
(n=28)
Day 30 Day 90 Day 30 Day 90 Day 30 Day 90
Liver disease severity
MELD score –0·3 (–0·8 to 0·2) –0·5 (–1·5 to 1·1) 0·0 (–1·0 to 1·0) –0·5 (–1·7 to 0·5) –0·1 (–2·2 to 1·0) –0·5 (–1·3 to 1·0)
UKELD score –1·0 (–2·2 to 0·4) –0·1 (–3·2 to 1·7) –0·3 (–1·1 to 1·0) 0·5 (–1·0 to 1·4) –1·0 (–1·9 to –0·2) –0·5 (–1·2 to 0·5)
Child-Pugh score 0·0 (0·0 to 0·0) 0·0 (0·0 to 0·0) 0·0 (0·0 to 1·0) 0·0 (0·0 to 1·0) 0·0 (–1·0 to 1·0) 0·0 (0·0 to 1·0)
Full blood count
Haemoglobin (g/dL) –0·1 (–0·7 to 0·4) 0·3 (–0·6 to 0·5) –1·0 (–1·4 to –0·4)* –0·3 (–0·6 to 0·5) –1·0 (–1·6 to –0·4)† –0·4 (–1·0 to 0·4)
White blood cells 
(× 10⁹ per L)
0·4 (–0·3 to 1·0) 0·3 (–0·2 to 0·6) –0·7 (–1·1 to –0·2)‡ –0·1 (–0·8 to 0·6) –1·0 (–1·6 to –0·3)§ –0·2 (–1·1 to 0·5)
Platelets (× 10⁹ per L) 2·0 (–7·0 to 9·0) –0·5 (–8·0 to 9·0) 13·0 (2·0 to 23·5)¶ 0·0 (–8·0 to 7·0) 8·0 (–4·0 to 30·0) 1·0 (–3·0 to 5·0)
Biochemistry
Sodium (mmol/L) 1·0 (–1·0 to 4·0) 0·0 (–2·0 to 3·0) 0·0 (–1·0 to 2·0) –1·0 (–2·0 to 1·0) 1·0 (–1·0 to 3·0) 0·0 (–1·0 to 3·0)
Potassium (mmol/L) 0·0 (–0·2 to 0·2) 0·1 (–0·1 to 0·3) 0·0 (–0·2 to 0·3) 0·2 (–0·2 to 0·5) –0·1 (–0·3 to 0·2) –0·1 (–0·3 to 0·3)
Urea (mmol/L) 0·3 (–0·1 to 0·9) 0·1 (–0·4 to 1·0) 0·0 (–0·5 to 0·7) 0·2 (–0·6 to 0·9) 0·2 (–0·6 to 0·5) –0·1 (–1·0 to 0·4)
Creatinine (µmol/L) 3·0 (–2·0 to 5·0) 1·0 (–2·0 to 10·0) 2·0 (–5·0 to 4·0) 2·5 (–1·0 to 10·0) 1·0 (–3·0 to 8·0) 1·5 (–4·0 to 9·0)
Liver function tests
Total bilirubin 
(µmol/L)
–5·0 (–9·0 to 3·0) –5·0 (–12·0 to 3·0) –2·0 (–10·0 to 8·0) –6·0 (–12·0 to –1·0) –2·5 (–9·5 to 10·0) –2·0 (–9·0 to 7·0)
Albumin (g/L) 0·0 (–3·0 to 1·0) 0·0 (–3·0 to 1·0) –2·0 (–3·0 to –1·0) –2·0 (–3·0 to 0·0) –3·0 (–4·0 to –1·0) –1·0 (–4·0 to 2·0)
International 
normalised ratio
0·0 (0·0 to 0·0) 0·0 (–0·1 to 0·1) 0·0 (–0·1 to 0·1) 0·0 (–0·1 to 0·1) 0·0 (–0·1 to 0·1) 0·0 (0·0 to 0·0)
Alanine 
aminotransferase 
(IU/L)
1·0 (–4·0 to 3·0) 0·0 (–4·0 to 4·0) –3·0 (–7·0 to 1·0) –2·0 (–9·0 to 4·0) –2·5 (–5·0 to 0·0) –4·5 (–8·0 to 0·0)
Aspartate 
aminotransferase 
(IU/L)
–0·5 (–6·0 to 5·0) –2·0 (–6·0 to 4·0) –3·0 (–8·0 to 2·0) –4·0 (–13·5 to 4·0) –3·0 (–9·0 to 1·0) –2·0 (–9·0 to 1·0)
γ glutamyl 
transferase (IU/L)
–1·0 (–7·0 to 3·0) –1·0 (–7·0 to 3·0) –8·0 (–22·5 to 0·0) –10·0 (–42·5 to 0·5) –5·0 (–22·0 to 1·0) –3·0 (–18·0 to 1·0)
Alkaline 
phosphatase (IU/L)
–8·0 (–28·0 to 14·0) –4·0 (–20·0 to 11·0) 7·0 (–8·0 to 21·0) –5·0 (–16·0 to 7·0) 8·0 (0·0 to 11·0) 1·5 (–10·0 to 24·0)
α fetoprotein (AFP) 0·0 (0·0 to 0·0) 0·0 (–1·0 to 1·0) 0·0 (–1·0 to 0·0) 0·0 (–1·0 to 0·0) 0·0 (–0·5 to 0·0) 0·0 (–1·0 to 0·0)
Non-invasive hepatic biomarkers
Enhanced Liver 
Fibrosis (ELF)
·· –0·1 (–0·4 to 0·6) ·· 0·0 (–0·4 to 1·0) ·· 0·1 (–0·6 to 0·5)
Fibroscan ·· 0·0 (–1·6 to 8·6) ·· 0·0 (–11·9 to 9·5) ·· 0·5 (–3·8 to 10·1)
Quality of life
Overall CLDQ score ·· 0·2 (–0·1 to 0·6) ·· –0·1 (–0·4 to 0·3) ·· 0·0 (–0·2 to 0·2)
Values are change in medians (IQR). Statistical comparisons were made between change at day 30 and 90 to baseline between the treatment and control groups, and unless 
indicated, there were no significant differences. G-CSF=granulocyte colony-stimulating factor. UKELD=UK End-Stage Liver Disease Score. CLDQ=Chronic Liver Disease 
Questionnaire. *p=0·0017. †p=0·0006. ‡p=0·0024. §p=0·0002. ¶p=0·0053.
Table 3: Change in liver parameters from baseline to day 30 and day 90
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were well characterised within a narrow range of MELD 
scores (11·50–15·50) and with respect to potentially 
confounding effects such as the duration of abstinence 
from alcohol and concomitant use of antiviral therapy. 
The study also used a defined stem-cell population, which 
is important for regulatory and scientific reasons; in 
animal models, mixed bone marrow infusions have been 
reported to contribute to liver fibrosis,4 whereas purified 
HSCs reduce fibrosis.6 CD133-positive cells represent a 
more enriched subpopulation of the CD34-positive cells, 
with true pluripotent stem cells constituting about 
0·1% of a CD133-positive population.17 Moreover 
CD133-selected cells have previously been infused in 
patients with liver9 and cardiovascular disease,18 producing 
benefits and with no safety concerns. We chose the dose 
used in this study (0·2 × 10⁶ cells per kg per infusion) 
because it was higher than that used in previous studies 
and we felt it to be achievable. Notably, in several patients, 
this amount of cells could not be mobilised, suggesting 
that our chosen number of cells might have been too 
high. CD133-positive doses of up to 2·5 × 10⁶ cells per kg 
have been used during bone marrow transplantation, 
although this was in the setting of bone marrow 
malignancy and chemotherapy.
Another strength of this study was the inclusion of a 
stand-alone G-CSF group. Results from a dose-finding 
study have showed that G-CSF at a dose of 15 µg/kg 
per day for 5 days was safe in patients with cirrhosis and 
was deemed to be the optimum dose for effective 
stem-cell mobilisation without adverse effects.19 This 
dose is higher than the routinely used dose of 10 µg/kg 
per day because patients with cirrhosis have a poorer 
mobilisation capacity than other patients, which is 
possibly related to splenic sequestration and poor bone 
marrow function. This dose was well tolerated by 
patients and no adverse effects were recorded. Another 
previous study that used the standard dosage showed a 
reversible increase in spleen size.20 While G-CSF is used 
to mobilise cells for leukapheresis, it has also been 
reported to improve liver regeneration and function in 
preclinical studies21 and to improve mortality in a 
clinical trial of acute-on-chronic liver failure in India, 
possibly through a reduction in deaths from sepsis.22 
Although differing in dose and clinical target from the 
study by Garg and colleagues,22 our study found no 
evidence of any benefit for the use of G-CSF in terms of 
liver fibrosis or function, or indeed sepsis, as has 
previously been reported.
A potential limitation of the study could be the absence 
of a true placebo and masking of treatment allocation, 
although in the absence of an effect this point is less 
pertinent. Given the overt side-effects of G-CSF (eg, bone 
pain), a placebo would be readily unmasked, whereas 
sham leukapheresis would pose ethical challenges.
Standard care G-CSF only G-CSF plus CD133-positive cell infusion
Deaths
Event 1 Variceal bleed (2·3 months) ·· Myocardial infarction (3·9 months)
Event 2 ·· ·· Progressive liver disease (8·9 months)
Assessed for liver transplant
Event 1 Assessed due to decompensation 
(7·9 months); not listed due to ventricular 
tachycardias on electrocardiogram
Assessed and listed due to decompensation 
(1·7 months); transplanted (4·3 months)
Assessed and listed due to decompensation 
(3·9 months); transplanted (10·2 months)
Event 2 ·· Assessed and listed due to decompensation 
(4·9 months); transplanted (16·9 months)
Assessed and listed due to decompensation 
(10·0 months); transplanted (13·6 months)
Event 3 ·· Assessed and listed due to poor synthetic function 
(5·1 months); listed but removed due to 
improvement
Assessed and listed due to decompensation 
(10·5 months); not transplanted
Event 4 ·· Assessed and listed due to decompensation 
(12·0 months); transplanted (15·0 months)
··
Serious adverse events
Event 1 Hypoglycaemia (2·4 months)* Oesophageal variceal bleed (2·1 months)* Diarrhoea and pulmonary sepsis (0·8 months)
Event 2 Hepatic decompensation (2·3 months) 
and later died
Urinary retention and ascites (1·7 months)* Sepsis and encephalopathy (2·3 months);* 
acute kidney injury (2·8 months)*
Event 3 ·· Hepatic decompensation and ascites (3·0 months)* Cardiac failure (5·8 months)*
Event 4 ·· ·· Ascites and encephalopathy (0·7 months);* 
ascites and encephalopathy (2·3 months)*
Event 5 ·· ·· Abdominal sepsis (0·3 months)*
Event 6 ·· ·· Peripheral oedema (1·7 months)*
Event 7 ·· ·· Sepsis and ascites (1·6 months)*
Event 8 ·· ·· Encephalopathy (2·0 months)*
Unless indicated otherwise, events represent different patients within the study. G-CSF=granulocyte colony-stimulating factor. *Resolved with no sequelae.
Table 4: Adverse events
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Another limitation is the absence of a histological 
endpoint. Although histological analysis to assess the 
effect on fibrosis and hepatocyte proliferation might 
have been revealing, we considered this to be unlikely. 
Microscopic analysis of needle biopsy material in 
patients with cirrhosis can be misleading because of the 
macrohistological nature of the disease. For example, 
biopsy of regenerative nodules surrounded by bands of 
fibrosis can have the appearance of normal liver, and 
different stages of fibrosis can be seen when multiple 
biopsies are taken from the same liver at transplantation.23 
Furthermore, in the setting of cirrhosis and coagulopathy, 
two biopsies within a short timeframe would constitute a 
substantial undertaking not without clinical risk; even 
transjugular liver biopsy in patients with cirrhosis has 
major complications (eg, perforation of the hepatic 
capsule, cholangitis, and intraperitoneal bleeding) in 1–3% 
of cases. Mortality related to the procedure varies from 
0·2% to 0·3%.24 Indeed, it is not clear that regulatory 
approval would even be granted for such a study in western 
Europe or the USA. Finally, this trial was powered on a 
clinically relevant marker of liver dysfunction, for which a 
liver biopsy would provide no relevant information. It is 
possible that the absence of histological confirmation of 
cirrhosis resulted in patients without cirrhosis being 
included, although this is very unlikely given that impaired 
liver synthetic function was a key inclusion criteria.
We decided not to track cells after infusion to confirm 
homing to the liver. Although these results would have 
been informative, the technical and regulatory barriers to 
non-invasively labelling and tracking such cells are 
substantial and there is a substantial risk that labelling of 
CD133-positive cells before their infusion could alter their 
viability and efficacy. While our published preclinical 
data6 suggested that HSCs efficiently engraft the recipient 
liver at first, there is minimal medium-term engraftment, 
and, notably, the HSCs induce longer-lasting changes in 
endogenous inflammatory cells such as macrophages.6 
Clinical data from the setting of alcoholic hepatitis also 
support this possibility.25
The absence of any effect of HSC infusions on liver 
fibrosis and function in this study differs from the 
positive effects reported by us and others in rodent 
models of liver fibrosis.6 This result comes despite the 
dose of cells and G-CSF being higher than that reported 
in other studies.8 Furthermore, given the failure to 
mobilise sufficient HSCs in all patients in this study, it 
would be difficult to aim for an even higher infused cell 
dose. Thus, this result is likely to be a true reflection of 
the lack of action of HSCs in the setting of advanced liver 
fibrosis and suggests caution when extrapolating the 
efficacy of any putative antifibrotic or proregenerative 
therapy in rodent models of fibrosis to the clinical setting. 
Fibrosis is qualitatively and quantitatively different in 
rodent models, with rodent fibrosis having less collagen 
cross-linking and more spontaneous remodelling than is 
typically seen in humans.26,27 Studies in rodents also often 
use freshly isolated cells derived from healthy animals, 
thus in this study, the use of autologous frozen cells 
might be relevant, although frozen cells are commonly 
used in bone marrow transplantation to good effect.
It is possible that the peripheral venous administration 
of the cells resulted in few cells reaching the liver, and in 
theory, direct administration of cells into the vessels 
supplying the liver (the portal vein and hepatic artery) 
might be more effective. However, this approach is 
invasive and carries substantial risks, including bleeding 
and thrombosis. Although such approaches were initially 
reported as being used without complications, a later 
study28 showed that direct infusions can lead to portal 
hypertensive bleeding following cell injection and another 
study29 was terminated early following complications in 
two of four patients after hepatic artery injection.29 
Moreover, the scientific literature does not support any 
advantage of directed infusion of cells to the liver over 
peripheral infusion.30
Our trial found no evidence to support any benefit 
from G-CSF alone or G-CSF plus stem-cell infusion in 
liver cirrhosis. Given the often intense enthusiasm 
surrounding stem-cell therapy, despite potential safety 
concerns,31 this important negative result reinforces the 
need for rigorous clinical trials to test efficacy in the field 
of stem cell-based therapy. This study also provides a 
template for future studies of novel anti-fibrotic therapies 
in patients with liver cirrhosis.
Contributors
ALK, SJF, and PNN had the original concept of the REALISTIC trial. 
SJF and PNN were the chief investigators. ALK, DS, SJF, and PNN 
designed the REALISTIC trial and, with DB (senior trial coordinator), RF, 
and CY, wrote and reviewed all protocol versions. ALK and DB submitted 
all REC, MHRA, and local research and development applications. RF, 
CY, DS, ALK, SJF, and PNN devised the statistical analysis plan, and RF 
did the statistical analysis for data management committee meetings and 
final publication, with statistical support from CY and DS. RF, CY, DS, 
and PNN interpreted the results. ALK, DB, DS, and KG wrote and 
designed the patient information sheets, external trial information, and 
patient CRFs. ALK, N-NT, JM, CC, ST, KG, and DHu and NG recruited 
patients to the trial and saw them at follow-up visits. HAB, JThoma, 
JThomp, AA, CB, NM, JC, and DHo were involved in processing of 
cellular material. PNN, SJF, RF, and CY wrote the manuscript and all 
authors reviewed the final version. PNN is the guarantor. 
Declaration of interests
We declare no competing interests.
Acknowledgments
The REALISTIC trial represents independent academic research funded 
by the National Institute for Health Research (NIHR) Birmingham Liver 
Biomedical Research Unit and the Sir Jules Thorne Charitable Trust. This 
Article presents independent research funded by the NIHR. The views 
expressed are those of the authors and not necessarily those of the NHS, 
the NIHR, or the Department of Health. The Sir Jules Thorn Charitable 
Trust also contributed funding to the Edinburgh component of the trial. 
RF and CY were funded by grant C22436/A15958 from Cancer Research 
UK. Chugai Pharmaceuticals supplied G-CSF at a 50% discount for this 
study. We thank the data monitoring committee, consisting of David 
Jones (DMC Chair; independent Liver expert), Mark Thursz (independent 
Liver expert), and Sarah Brown (Independent Senior Statistician) for their 
time and input. We also thank the NIHR Liver Biomedical Research Unit 
Patient and Public Involvement (PPI) group for their input into study 
design, as well as the NIHR/Wellcome Trust Clinical Research Facility at 
the University Hospital Birmingham NHS Foundation Trust. 
Articles
36 www.thelancet.com/gastrohep   Vol 3   January 2018
References
1 Williams R, Aspinall R, Bellis M, et al. Addressing liver disease in the 
UK: a blueprint for attaining excellence in health care and reducing 
premature mortality from lifestyle issues of excess consumption of 
alcohol, obesity, and viral hepatitis. Lancet 2014; 384: 1953–97.
2 Shiels MS, Chernyavskiy P, Anderson WF, et al. Trends in premature 
mortality in the USA by, race, and ethnicity from 1999 to 2014: 
an analysis of death certificate data. Lancet 2017; 389: 1043–54.
3 Di Marco V, Calvaruso V, Ferraro D, et al. Effects of eradicating 
hepatitis C virus infection in patients with cirrhosis differ with 
stage of portal hypertension. Gastroenterology 2016; 151: 130–39. e2.
4 Thomas JA, Pope C, Wojtacha D, et al. Macrophage therapy for 
murine liver fibrosis recruits host effector cells improving fibrosis, 
regeneration and function. Hepatology 2011; 53: 2003–15.
5 Sakaida I, Terai S, Yamamoto N, et al. Transplantation of bone 
marrow cells reduces CCl4-induced liver fibrosis in mice. 
Hepatology 2004; 40: 1304–11.
6 King A, Houlihan DD, Kavanagh D, et al. Sphingosine-1-phosphate 
prevents egress of hematopoietic stem cells from liver to reduce 
fibrosis. Gastroenterology 2017; 153: 233–48. e16.
7 Forbes SJ, Newsome PN. Liver regeneration—mechanisms and 
models to clinical application. Nat Rev Gastroenterol Hepatol 2016; 
13: 473–85.
8 Moore JK, Stutchfield BM, Forbes SJ. Systematic review: the effects 
of autologous stem cell therapy for patients with liver disease. 
Aliment Pharmacol Ther 2014; 39: 673–85.
9 Furst G, Schulte am EJ, Poll LW, et al. Portal vein embolization and 
autologous CD133+ bone marrow stem cells for liver regeneration: 
initial experience. Radiology 2007; 243: 171–79.
10 Lyra AC, Soares MB, da Silva LF, et al. Infusion of autologous bone 
marrow mononuclear cells through hepatic artery results in a 
short-term improvement of liver function in patients with chronic 
liver disease: a pilot randomized controlled study. 
Eur J Gastroenterol Hepatol 2010; 22: 33–42.
11 Salama H, Zekri AR, Bahnassy AA, et al. Autologous CD34+ and 
CD133+ stem cells transplantation in patients with end stage liver 
disease. World J Gastroenterol 2010; 16: 5297–305.
12 Spahr L, Chalandon Y, Terraz S, et al. Autologous bone marrow 
mononuclear cell transplantation in patients with decompensated 
alcoholic liver disease: a randomized controlled trial. PLoS One 
2013; 8: e53719.
13 King A, Barton D, Beard HA, et al. REpeated AutoLogous Infusions 
of STem cells In Cirrhosis (REALISTIC): a multicentre, phase II, 
open-label, randomised controlled trial of repeated autologous 
infusions of granulocyte colony-stimulating factor (GCSF) 
mobilised CD133+ bone marrow stem cells in patients with 
cirrhosis. A study protocol for a randomised controlled trial. 
BMJ Open 2015; 5: e007700.
14 Said A, Williams J, Holden J, et al. Model for end stage liver disease 
score predicts mortality across a broad spectrum of liver disease. 
J Hepatol 2004; 40: 897–903.
15 Ripoll C, Groszmann R, Garcia-Tsao G, et al. Hepatic venous 
pressure gradient predicts clinical decompensation in patients with 
compensated cirrhosis. Gastroenterology 2007; 133: 481–88.
16 Yoon YJ, Friedman SL, Lee YA. Antifibrotic therapies: where are we 
now? Semin Liver Dis 2016; 36: 87–98.
17 Goussetis E, Theodosaki M, Paterakis G, et al. A functional 
hierarchy among the CD34+ hematopoietic cells based on in vitro 
proliferative and differentiative potential of AC133+CD34(bright) 
and AC133(dim/)-CD34+ human cord blood cells. 
J Hematother Stem Cell Res 2000; 9: 827–40.
18 Noiseux N, Mansour S, Weisel R, et al. The IMPACT-CABG trial: 
a multicenter, randomized clinical trial of CD133+ stem cell therapy 
during coronary artery bypass grafting for ischemic 
cardiomyopathy. J Thorac Cardiovasc Surg 2016; 152: 1582–88. e2.
19 Lorenzini S, Isidori A, Catani L, et al. Stem cell mobilization and 
collection in patients with liver cirrhosis. Aliment Pharmacol Ther 
2008; 27: 932–39.
20 Gaia S, Smedile A, Omede P, et al. Feasibility and safety of G-CSF 
administration to induce bone marrow-derived cells mobilization in 
patients with end stage liver disease. J Hepatol 2006; 45: 13–19.
21 Piscaglia AC, Shupe TD, Oh SH, Gasbarrini A, Petersen BE. 
Granulocyte-colony stimulating factor promotes liver repair and 
induces oval cell migration and proliferation in rats. 
Gastroenterology 2007; 133: 619–31.
22 Garg V, Garg H, Khan A, et al. Granulocyte colony-stimulating 
factor mobilizes CD34(+) cells and improves survival of patients 
with acute-on-chronic liver failure. Gastroenterology 2012; 
142: 505–12. e1.
23 Garrido MC, Hubscher SG. Accuracy of staging in primary biliary 
cirrhosis. J Clin Pathol 1996; 49: 556–59.
24 Garcia-Compean D, Cortes C. Transjugular liver biopsy. An update. 
Ann Hepatol 2004; 3: 100–03.
25 Lanthier N, Lin-Marq N, Rubbia-Brandt L, Clement S, Goossens N, 
Spahr L. Autologous bone marrow-derived cell transplantation in 
decompensated alcoholic liver disease: what is the impact on liver 
histology and gene expression patterns? Stem Cell Res Ther 2017; 
8: 88.
26 Campana L, Iredale JP. Regression of liver fibrosis. Semin Liver Dis 
2017; 37: 1–10.
27 Iredale JP. Models of liver fibrosis: exploring the dynamic nature of 
inflammation and repair in a solid organ. J Clin Invest 2007; 
117: 539–48.
28 Salama H, Zekri AR, Zern M, et al. Autologous hematopoietic stem 
cell transplantation in 48 patients with end-stage chronic liver 
diseases. Cell Transplant 2010; 19: 1475–86.
29 Mohamadnejad M, Namiri M, Bagheri M, et al. Phase 1 human trial 
of autologous bone marrow-hematopoietic stem cell transplantation 
in patients with decompensated cirrhosis. World J Gastroenterol 
2007; 13: 3359–63.
30 Houlihan DD, Newsome PN. Critical review of clinical trials of 
bone marrow stem cells in liver disease. Gastroenterology 2008; 
135: 438–50.
31 Kuriyan AE, Albini TA, Townsend JH, et al. Vision loss after 
intravitreal injection of autologous “stem cells” for AMD. 
N Engl J Med 2017; 376: 1047–53.
